Arcus Biosciences, Inc.
Financials
Valuation Metrics
Arcus Biosciences, Inc.'s Market Cap is $2.29B. At end of 2025 it was $2.56B. Ranked #1880 of 3,118 in US market (top 60%), #1193 of 1,644 on NYSE (top 73%), #120 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.29B | US#1,880/3,118 Sec#120/265 |
| Revenue | $97M | US#2,681/3,118 Sec#126/265 |
| Net Income | $-452M | US—/3,118 Sec—/265 |
| Total Assets | $924M | US#2,504/3,118 Sec#107/265 |
| Net Assets | $464M | US#2,268/3,118 Sec#115/265 |
| Employees | 601 | US#2,188/3,118 Sec#74/265 |
| Value | ||
| P/B | 4.93x | US#2,218/3,118 Sec#141/265 |
| P/S | 23.57x | US#2,867/3,118 Sec#149/265 |
| FCF Yield | -20.77% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -97.41% | US#2,778/3,118 Sec#202/265 |
| ROA | -48.92% | US#2,978/3,118 Sec#211/265 |
| Op. Margin | -501.03% | US#2,781/3,118 Sec#153/265 |
| Revenue Growth | -62.84% | US#2,703/3,118 Sec#164/265 |
| Financial Health | ||
| Debt Ratio | 99.14% | US#1,085/3,118 Sec#163/265 |
| Total Debt | $114M | US#2,390/3,118 Sec#113/265 |
| FCF | $-475M | US#2,893/3,118 Sec#250/265 |
| Cash | $150M | US#1,950/3,118 Sec#133/265 |
| Current Ratio | 3.82x | US#596/3,118 Sec#164/265 |
| Performance | ||
| 1Y Return | -9.96% | US#2,133/3,118 Sec#167/265 |
| 1M Return | -29.62% | US#2,977/3,118 Sec#249/265 |
| From 52W High | -42.72% | US#2,428/3,118 Sec#175/265 |
| 1Y MDD | -43.74% | US#2,110/3,118 Sec#140/265 |
| Trading | ||
| Volume | 1,396,602 shares | US#1,228/3,118 Sec#117/265 |
| Trading Value | $26M | US#1,729/3,118 Sec#125/265 |
| Per Share | ||
| EPS | $-3.59 | US—/3,118 Sec—/265 |
| BPS | $3.69 | US#2,389/3,118 Sec#144/265 |
Company Info
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.